AbbVie Inc (ABBV) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Total Assets Chart for AbbVie Inc
AbbVie Inc (ABBV) total assets for FY2025 were USD 134.0B, a -0.9% change from FY2024. AbbVie Inc's total assets grew from USD 21.1B in 2010 to USD 134.0B in 2025 (533.8% over 15 years). Total assets compound annual growth rate: 5-year CAGR of -2.3%, 10-year CAGR of 9.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $430.95B
- Implied Share Price
- $243.87
- Enterprise Value
- $506.83B
- Revenue (TTM)
- $64.39B
- EBITDA
- $30.76B
- Profit Margin
- 9.80%
- Trailing P/E
- 69.48
- Forward P/E
- 17.79
- Price/Book (MRQ)
- 50.46
- Price/Sales (TTM)
- 6.69
- EV/EBITDA
- 44.16
- EV/Revenue
- 7.87
- Dividend Yield
- 2.77%
- Book Value
- $-3.36
- Free Cash Flow (FY2025)
- $17.82B
- Free Cash Flow Yield
- 4.13%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.